The availability, and the ongoing development, of specific PKCθ inhibitors, some of which are already in clinical trials for immune disorders, thus opens new perspectives for pharmacological approach to muscular dystrophy [15], [19]. The gene discussed is PRRT2; the disease is immune system disorder.